• Company
• 'Trodelvy' approved for prescription at general hospitals
• by Eo, Yun-Ho Aug 20, 2024 06:34am

• Company
• Reimb remains an issue despite broadened options for UC
• by Moon, sung-ho Aug 20, 2024 06:34am

• Company
• K-Pharma focuses on developing CAR-NK cell therapies
• by Son, Hyung-Min Aug 20, 2024 06:34am

• Company
• Will Handok’s Empaveli be reimbursed in 1H in KOR?
• by Eo, Yun-Ho Aug 19, 2024 05:47am

• Company
• Will Astellas’ gastric cancer drug Vyloy be approved in 2H?
• by Eo, Yun-Ho Aug 19, 2024 05:47am

• Company
• Entresto faces competition in the heart failure market
• by Moon, sung-ho Aug 19, 2024 05:47am

• Company
• Twice-yearly Uplizna enters last stage to reimb in KOR
• by Eo, Yun-Ho Aug 16, 2024 05:56am

• Company
• OraTicx signs a distribution deal with U.S.-based Stratum
• by Son, Hyung-Min Aug 16, 2024 05:56am

• Company
• K-Pharma speeds up marketing new drugs for bile duct cancer
• by Son, Hyung-Min Aug 16, 2024 05:55am

• Company
• LG Chem begins Phase 2 trials for infant hexavalent vaccine
• by Hwang, Byung-woo Aug 14, 2024 05:51am